Ligand Pharmaceuticals (LGND) Competitors

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 46.42% compared to ANI Pharmaceuticals' net margin of 8.87%. ANI Pharmaceuticals' return on equity of 27.97% beat Ligand Pharmaceuticals' return on equity.

Ligand Pharmaceuticals presently has a consensus price target of $256.29, suggesting a potential upside of 21.85%. ANI Pharmaceuticals has a consensus price target of $107.33, suggesting a potential upside of 27.91%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

In the previous week, Ligand Pharmaceuticals had 12 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 18 mentions for Ligand Pharmaceuticals and 6 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.76 beat Ligand Pharmaceuticals' score of 0.53 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Ligand Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Ligand Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 46.42% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat Ligand Pharmaceuticals' return on equity.

Ligand Pharmaceuticals presently has a consensus price target of $256.29, suggesting a potential upside of 21.85%. Neurocrine Biosciences has a consensus price target of $183.75, suggesting a potential upside of 22.84%. Given Neurocrine Biosciences' higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Ligand Pharmaceuticals.

In the previous week, Neurocrine Biosciences had 25 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 43 mentions for Neurocrine Biosciences and 18 mentions for Ligand Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.69 beat Ligand Pharmaceuticals' score of 0.53 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Ligand Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.

Neurocrine Biosciences has higher revenue and earnings than Ligand Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Ligand Pharmaceuticals has a net margin of 46.42% compared to Ionis Pharmaceuticals' net margin of -30.91%. Ligand Pharmaceuticals' return on equity of 13.86% beat Ionis Pharmaceuticals' return on equity.

Ligand Pharmaceuticals has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 2.6% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 20 mentions for Ionis Pharmaceuticals and 18 mentions for Ligand Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.62 beat Ligand Pharmaceuticals' score of 0.53 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Ionis Pharmaceuticals presently has a consensus price target of $99.35, suggesting a potential upside of 30.69%. Ligand Pharmaceuticals has a consensus price target of $256.29, suggesting a potential upside of 21.85%. Given Ionis Pharmaceuticals' higher possible upside, equities analysts plainly believe Ionis Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Ligand Pharmaceuticals has a net margin of 46.42% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Ligand Pharmaceuticals' return on equity of 13.86% beat Madrigal Pharmaceuticals' return on equity.

Ligand Pharmaceuticals has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ligand Pharmaceuticals had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 18 mentions for Ligand Pharmaceuticals and 16 mentions for Madrigal Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.53 beat Madrigal Pharmaceuticals' score of 0.49 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Madrigal Pharmaceuticals presently has a consensus price target of $682.07, suggesting a potential upside of 27.52%. Ligand Pharmaceuticals has a consensus price target of $256.29, suggesting a potential upside of 21.85%. Given Madrigal Pharmaceuticals' higher possible upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.